Available evidence from clinical trials suggests that, compared with placebo or moderate-dose statin treatment, high-dose intensive statin therapy significantly reduces incident CV outcomes. This ...

Stopping statin treatment early could substantially reduce lifetime protection against heart disease since a large share of the benefit occurs later in life. That's the finding of a recent modelling ...

ICU statin therapy was associated with reduced 30-day mortality in patients with intracerebral haemorrhage and acute kidney ...

Cardiovascular disease (CVD) risk was reduced by 1.2% in the intention-to-treat analysis and 5% in the per protocol analysis for adults aged 75 and older. The study looked at 2 main age groups: 75 to ...

Understanding your risk for developing atherosclerotic cardiovascular disease (ASCVD) plays an important role in deciding whether to start statin therapy. While there are recommendations and risk ...

Every 33 seconds one person dies from cardiovascular disease, according to the Centers for Disease Control and Prevention (CDC). In a single year, an estimated 805,000 Americans will suffer from a ...

Dr Riddock explains how the ASCVD treatment landscape lends itself to initiation of therapy beyond statins in the inpatient setting. Ian Riddock, MD: Within the inpatient setting when recognizing that ...

Statins are the first-line therapy for atherosclerotic cardiovascular disease (ASCVD) risk reduction. Statins have also been shown to be safe and well-tolerated in properly selected patients, similar ...

ORLANDO, Fla. — Patients with type 1 and 2 diabetes who delay treatment with recommended statin therapy to address the well-known high risk for cardiovascular (CV) events show significantly higher ...

More than one in four patients in the United States with atherosclerotic cardiovascular disease (ASCVD) are not on a guideline-recommended statin or other lipid-lowering therapy, with suboptimal ...